Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
* @# ~+ W5 `5 W3 A, t& ZNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # F" D" S! _& d
+ Author Affiliations
' d: E. x" _, q% L& I
# y }' x- f' K2 d: C; K5 U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 9 z& E) {( ~1 T
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan . T5 x+ y- P! s3 J) X
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
% x! x" N, G& m) e6 p2 H+ |4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 6 k8 D% t' _6 h4 N' O& s8 H; p1 G
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ( F9 }: f/ p L8 ~
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
' W$ u' I+ M) p7 r' t7Kinki University School of Medicine, Osaka 589-8511, Japan
( G2 S+ h2 F' S8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 i# _* M3 c. w
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan + _7 J$ q! p2 k' T7 V }, q
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
& A$ b* y6 K8 W p6 g+ _& H# {AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ( t$ t N, H6 I2 u% y) w5 J
2 E4 r, Y& f' J* l" g2 U |